Drugs / LXE408
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07809919 | Dec 2018 → Sep 2021 | Chagas disease, visceral leishmaniasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06997159 | Jun 2026 → Apr 2028 expected | cutaneous leishmaniasis | Drugs for Neglected Diseases | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06632600 | Apr 2025 → Jul 2027 expected | Chagas disease | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 2 | NCT05957978 | Mar 2024 → Jun 2025 | visceral leishmaniasis | Drugs for Neglected Diseases | Completed | No outcome recorded |
| Phase 2 | NCT05593666 | Dec 2022 → Apr 2025 | visceral leishmaniasis | Drugs for Neglected Diseases | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LXE408 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05593666 ↗ |
| Modality | Small molecule | — CHEMBL4748352 ↗ |
| Route | Oral | “LXE408 orally once daily for 14 days” NCT05957978 ↗ |